Rite Aid Corporation (RADCQ)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Rite Aid Corporation (RADCQ) trades at $0.01. Rite Aid Corporation operates a chain of retail drugstores in the United States, providing prescription drugs, over-the-counter medications, and pharmacy services. Market cap: $559,740, Sector: Healthcare.
Price live · AI analysis from Mar 16, 2026Analyst Coverage for RADCQ: RADCQ does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates RADCQ against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
RADCQ: 1/1 perspectives are bearish.
How is this calculated? →Rite Aid Corporation (RADCQ) Healthcare & Pipeline Overview
Rite Aid Corporation, founded in 1962, operates retail pharmacies and provides pharmacy benefit management services. Facing financial challenges, the company filed for Chapter 11 bankruptcy in 2023. It competes with larger players in a consolidating healthcare market while focusing on retail pharmacy and healthcare service offerings.
What Is the Investment Thesis for RADCQ?
Rite Aid Corporation's Chapter 11 reorganization presents both opportunities and risks for investors. The company's restructuring aims to address financial challenges and optimize its operations. Key value drivers include streamlining the business, reducing debt, and enhancing operational efficiency. Growth catalysts involve expanding healthcare services and improving the PBM segment. Potential risks include the successful execution of the reorganization plan, competition from larger pharmacy chains, and the evolving healthcare landscape. Monitoring the company's progress in debt reduction and operational improvements will be crucial. The company's profit margin is -3.0% and gross margin is 19.9%.
Based on FMP financials and quantitative analysis
RADCQ Key Highlights
- Rite Aid filed for Chapter 11 bankruptcy on October 15, 2023, indicating significant financial distress.
- The company operates two segments: Retail Pharmacy and Pharmacy Services.
- Rite Aid offers a wide range of products, including prescription drugs, over-the-counter medications, and health and beauty aids.
- The Pharmacy Services segment provides pharmacy benefit management (PBM) solutions.
- Rite Aid's profit margin is -3.0%, reflecting ongoing financial challenges.
Who Are RADCQ's Competitors?
RADCQ is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ATAI Atai Beckley NV is a clinical-stage biopharmaceutical company focused on developing treatments for mental health disorders. The company | $4.88 | -5.97% | $1.80B | 68 |
| MEDS TRxADE HEALTH, Inc. | $7.59 | +4.55% | $13.28M | 63 |
| ONC BeOne Medicines Ltd. | $309.46 | +3.97% | $33.07B | 61 |
| NEUP Neuphoria Therapeutics Inc. | $3.44 | +1.78% | $18.59M | 60 |
| YI 111, Inc. | $4.13 | -0.12% | $36.04M | 44 |
| ALBHF Alibaba Health Information Technology Limited | $0.42 | +2.44% | $6.77B | 45 |
| WBA Walgreens Boots Alliance operates as a pharmacy-led health and beauty retail company with a global presence. The company | $11.98 | +0.50% | $10.37B | 45 |
| IPXL Impax Laboratories, Inc. | $18.30 | +0.55% | 46 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are RADCQ's Key Strengths?
- Established retail pharmacy network
- Pharmacy benefit management (PBM) capabilities
- Brand recognition and customer loyalty
- Online retail platform
What Are RADCQ's Weaknesses?
- High debt levels
- Negative profit margin
- Chapter 11 bankruptcy
- Intense competition
What Could Drive RADCQ Stock Higher?
- Successful execution of Chapter 11 reorganization plan.
- Streamlining operations and reducing debt.
- Expansion of healthcare services and PBM offerings.
What Are the Key Risks for RADCQ?
- Financial-distress signal — its Altman Z-Score of 0.85 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Competition from larger pharmacy chains.
- Changes in healthcare regulations.
- Economic downturn.
- Generic drug pricing pressures.
- Successful emergence from Chapter 11 is not guaranteed.
What Are the Growth Opportunities for RADCQ?
- Expansion of Healthcare Services: Rite Aid can grow by expanding its healthcare service offerings, such as immunizations, health screenings, and chronic disease management programs. The market for these services is growing as healthcare providers seek to improve patient outcomes and reduce costs. By leveraging its retail pharmacy locations, Rite Aid can provide convenient access to these services. Timeline: Ongoing.
- Enhancement of Pharmacy Benefit Management (PBM) Services: Rite Aid can enhance its PBM services by offering more comprehensive solutions, such as data analytics, formulary management, and patient engagement programs. The PBM market is growing as employers and health plans seek to control prescription drug costs. By investing in technology and expertise, Rite Aid can attract new clients and retain existing ones. Timeline: Ongoing.
- Online Retail Expansion: Rite Aid can expand its online retail presence by offering a wider range of products and services, such as online prescription refills, virtual consultations, and home delivery. The online retail market is growing as consumers seek convenient and accessible healthcare solutions. By investing in its online platform, Rite Aid can reach new customers and increase sales. Timeline: Ongoing.
- Strategic Partnerships: Rite Aid can form strategic partnerships with other healthcare providers, such as hospitals, clinics, and physician groups, to expand its reach and offer more comprehensive services. These partnerships can help Rite Aid attract new patients and improve patient outcomes. By collaborating with other providers, Rite Aid can create a more integrated healthcare ecosystem. Timeline: Ongoing.
- Focus on Specialty Pharmacy: Rite Aid can focus on specialty pharmacy services, which involve dispensing and managing complex medications for chronic conditions. The specialty pharmacy market is growing as the prevalence of chronic diseases increases. By investing in specialized expertise and infrastructure, Rite Aid can capture a larger share of this market. Timeline: Ongoing.
What Opportunities Does RADCQ Have?
- Expansion of healthcare services
- Enhancement of PBM services
- Online retail expansion
- Strategic partnerships
What Threats Does RADCQ Face?
- Competition from larger pharmacy chains
- Changes in healthcare regulations
- Economic downturn
- Generic drug pricing pressures
What Are RADCQ's Competitive Advantages?
- Established retail pharmacy network
- Pharmacy benefit management (PBM) capabilities
- Brand recognition and customer loyalty
- Online retail platform
What Does RADCQ Do?
Rite Aid Corporation, established in 1962, has evolved into a significant retail drugstore chain in the United States. Headquartered in Philadelphia, Pennsylvania, the company operates through two segments: Retail Pharmacy and Pharmacy Services. The Retail Pharmacy segment offers a wide array of products, including prescription drugs, over-the-counter medications, health and beauty aids, personal care items, seasonal merchandise, cosmetics, household goods, food, beverages, and pet care products. This segment also provides healthcare services such as immunizations, blood pressure monitoring, cholesterol and diabetes assistance, and medication management guidance. The Pharmacy Services segment delivers integrated pharmacy benefit management (PBM) solutions, including technology, mail delivery, specialty pharmacy services, network and rebate administration, claims adjudication, and pharmacy discount programs. These services cater to health plans, commercial employers, labor groups, and state and local governments. Rite Aid also extends its reach through an online retail platform. On October 15, 2023, Rite Aid and its affiliates voluntarily filed for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of New Jersey, signaling a strategic restructuring effort to address financial challenges.
What Products and Services Does RADCQ Offer?
- Operates retail drugstores in the United States
- Sells prescription drugs and over-the-counter medications
- Offers health and beauty aids, personal care products, and seasonal merchandise
- Provides healthcare services such as immunizations and health screenings
- Offers pharmacy benefit management (PBM) services
- Provides mail delivery and specialty pharmacy services
- Operates an online retail site
How Does RADCQ Make Money?
- Sells products and services through retail drugstores
- Provides pharmacy benefit management (PBM) services to health plans and employers
- Generates revenue from prescription drug sales and healthcare services
- Offers online retail sales of products and services
What Industry Does RADCQ Operate In?
Rite Aid operates in the competitive retail pharmacy and pharmacy benefit management (PBM) industry. The market is characterized by consolidation, with larger players like CVS and Walgreens dominating. Trends include increasing demand for pharmacy services, growing adoption of telehealth, and rising healthcare costs. Rite Aid's Chapter 11 reorganization reflects the challenges of competing in this environment. The company's focus on healthcare services and PBM offerings positions it to capitalize on evolving market dynamics.
Who Are RADCQ's Key Customers?
- Individual consumers seeking prescription drugs and healthcare products
- Health plans and employers seeking pharmacy benefit management (PBM) services
- Patients seeking healthcare services such as immunizations and health screenings
- Online customers seeking convenient access to products and services
How Rite Aid Corporation Is Valued
Rite Aid Corporation carries a market capitalization of 560K, placing it in the micro-cap category.
Company Profile
Rite Aid Corporation operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Philadelphia, US. The company is led by CEO Jeffrey Scott Stein. RADCQ has traded publicly since 1980.
ROE 276%Key Financial Metrics
Return on equity for Rite Aid Corporation stands at 276.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -10.0%, showing how much profit it generates from its asset base. A current ratio of 1.21 indicates the company holds enough short-term assets to cover its near-term obligations.
F-Score 3/9Financial Health
Rite Aid Corporation's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 0.85 places it in the distress zone, a signal of elevated financial risk.
FY2027 estForward Outlook
Wall Street analysts project Rite Aid Corporation revenue of about $24.07B for fiscal 2027, with EPS near $-2.82.
RADCQ Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's turnaround strategies, potentially indicating a positive outlook from leadership.
- Community sentiment has shown a slight uptick, with discussions around potential restructuring plans attracting interest.
- Market perception has improved as Rite Aid explores partnerships to enhance its service offerings, appealing to a broader customer base.
- Recent developments in health care policies may favor Rite Aid's business model, positioning it well for future growth.
Bear Case
- Concerns linger over Rite Aid's financial health, with ongoing discussions about debt levels and sustainability raising red flags among investors.
- Community sentiment remains mixed, with many expressing skepticism about the effectiveness of the company's turnaround efforts.
- Recent layoffs and store closures have sparked negative discussions, leading to fears about the company's ability to maintain market presence.
- The competitive landscape in retail pharmacy remains fierce, with rivals continuously innovating, which may hinder Rite Aid's recovery efforts.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
RADCQ Latest News
No recent news available for RADCQ.
RADCQ Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for RADCQ.
Price Targets
Wall Street price target analysis for RADCQ.
RADCQ MoonshotScore
What does this score mean?
The MoonshotScore rates RADCQ's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Jeffrey Scott Stein
Chief Executive Officer
Jeffrey Scott Stein serves as the Chief Executive Officer of Rite Aid Corporation. His background includes extensive experience in corporate restructuring and financial management. Prior to joining Rite Aid, Stein held leadership positions at various companies, focusing on turnaround strategies and operational improvements. His expertise lies in guiding organizations through complex financial situations and implementing strategic initiatives to drive growth and profitability. He is responsible for managing 47,000 employees.
Track Record: Since assuming the role of CEO, Jeffrey Scott Stein has been focused on navigating Rite Aid through its Chapter 11 reorganization. Key initiatives include streamlining operations, reducing debt, and enhancing the company's competitive position. Stein's leadership is crucial in guiding Rite Aid through this challenging period and positioning it for future success.
RADCQ OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Rite Aid does not meet the minimum financial standards required for the higher tiers (OTCQX and OTCQB). Companies in this tier may be distressed, undergoing bankruptcy, or have limited financial disclosure. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and financial transparency compared to NYSE or NASDAQ-listed companies. This tier often includes companies with speculative ventures or those facing severe financial difficulties.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure
- Higher price volatility
- Lower trading volumes
- Potential for fraud or manipulation
- Bankruptcy risk
- Verify the company's financial statements, if available
- Research the company's management team and their track record
- Assess the company's business model and competitive landscape
- Review any available news or press releases about the company
- Understand the risks associated with investing in OTC Other stocks
- Consult with a financial advisor before investing
- Check for any regulatory actions or investigations
- Established retail pharmacy network
- Pharmacy benefit management (PBM) capabilities
- Brand recognition and customer loyalty
What Investors Ask About Rite Aid Corporation (RADCQ) — Healthcare
What does Rite Aid Corporation do?
Rite Aid Corporation operates as a retail drugstore chain and pharmacy benefit management (PBM) provider in the United States. The company's retail pharmacies offer prescription drugs, over-the-counter medications, health and beauty aids, and other consumer products. Its PBM services include technology solutions, mail delivery, specialty pharmacy, and claims adjudication. Rite Aid serves individual consumers, health plans, commercial employers, and government entities. The company filed for Chapter 11 bankruptcy in October 2023 and is undergoing a restructuring process.
What do analysts say about RADCQ stock?
As of March 16, 2026, formal analyst ratings for RADCQ are limited due to its OTC listing and Chapter 11 bankruptcy status. Investors should focus on the company's progress in restructuring its debt, improving operational efficiency, and navigating the bankruptcy process. Key valuation metrics are less relevant in this situation, and the primary focus is on the company's ability to emerge from bankruptcy successfully and execute its turnaround strategy. Given the bankruptcy, the stock is highly speculative.
What are the main risks for RADCQ?
The main risks for Rite Aid Corporation include the successful execution of its Chapter 11 reorganization plan, competition from larger pharmacy chains, and changes in healthcare regulations. The company's high debt levels and negative profit margin pose significant financial challenges. Additionally, generic drug pricing pressures and the evolving healthcare landscape could impact Rite Aid's profitability. Investors should carefully consider these risks before investing in RADCQ.
What are the key factors to evaluate for RADCQ?
Evaluate RADCQ on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does RADCQ data refresh on this page?
RADCQ prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven RADCQ's recent stock price performance?
Rite Aid Corporation (RADCQ) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established retail pharmacy network. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RADCQ overvalued or undervalued right now?
Valuing Rite Aid Corporation (RADCQ) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying RADCQ?
Before investing in Rite Aid Corporation (RADCQ), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited or delayed.
- AI analysis pending for RADCQ.